Sofetabart Mipitecan

N/A

Report date: 2026/04/20 20:01:59

Base Information

Drug NameSofetabart Mipitecan
Drug Alias NameFRα Antibody-Drug Conjugate (Eli Lilly)LY4170156LY-4170156
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payload
Mechanisms of ActionAnti-FOLR1DNA topoisomerase I inhibitors
TargetsFolate receptor alphaDNA topoisomerase I
Therapy Area/IndicationsNeoplasm MetastasisUterine Cervical NeoplasmsEndometrial Neoplasms +[10
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[26
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisUterine Cervical NeoplasmsEndometrial Neoplasms +[10
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A